Skip to main content
SpringerLink
Log in

Risankizumab

  • Chapter
  • First Online:
Advances in Psoriasis

  • 651 Accesses

Abstract

Risankizumab is a humanized IgG1 monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23). It has demonstrated substantial clinical efficacy in the treatment of psoriasis. This chapter reviews the efficacy and safety of risankizumab for the treatment of psoriasis as evidenced by the clinical trials to date. Four phase III trials have shown risankizumab to be more effective than ustekinumab and adalimumab in terms of PASI and sPGA scores with similar safety profiles to placebo. Thus far, no significant safety concerns have emerged for this drug, though further long-term studies will be critical in confirming this.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–25. https://doi.org/10.1016/S1074-7613(00)00070-4.

    Article  CAS  PubMed  Google Scholar 

  2. Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616–26. https://doi.org/10.1111/jdv.14433.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–87. https://doi.org/10.1084/jem.20060244.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–74. https://doi.org/10.1016/S0140-6736(08)60725-4.

    Article  CAS  PubMed  Google Scholar 

  5. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–84. https://doi.org/10.1016/S0140-6736(08)60726-6.

    Article  CAS  PubMed  Google Scholar 

  6. Tsai T-F, Ho J-C, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154–63. https://doi.org/10.1016/j.jdermsci.2011.05.005.

    Article  CAS  PubMed  Google Scholar 

  7. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human Interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135(4):1130–41. https://doi.org/10.1053/j.gastro.2008.07.014.

    Article  CAS  PubMed  Google Scholar 

  8. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–30. https://doi.org/10.1084/jem.20030451.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222–6. https://doi.org/10.1038/nature14175.

    Article  CAS  PubMed  Google Scholar 

  10. Visvanathan S, Baum P, Vinisko R, et al. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. J Allergy Clin Immunol. 2018;143:2158–69. https://doi.org/10.1016/j.jaci.2018.11.042.

    Article  CAS  PubMed  Google Scholar 

  11. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–60. https://doi.org/10.1056/NEJMoa1607017.

    Article  CAS  PubMed  Google Scholar 

  12. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761105. Accessed May 23 2019.

  13. Visvanathan S, Baum P, Salas A, et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: results from a randomised phase II biopsy sub-study. J Crohns Colitis. 2018;12(10):1170–9. https://doi.org/10.1093/ecco-jcc/jjy099.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Feagan BG, Panés J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671–80. https://doi.org/10.1016/S2468-1253(18)30233-4.

    Article  PubMed  Google Scholar 

  15. Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709. https://doi.org/10.1016/S0140-6736(17)30570-6.

    Article  CAS  PubMed  Google Scholar 

  16. Baeten D, Østergaard M, Wei JC-C, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–302. https://doi.org/10.1136/annrheumdis-2018-213328.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. A study to evaluate risankizumab in adult and adolescent subjects with moderate to severe atopic dermatitis—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03706040?term=risankizumab&draw=2&rank=19. Accessed May 31 2019.

  18. Multicenter A. Randomized, double-blind, placebo controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapy—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03398148?term=risankizumab&draw=5&rank=23. Accessed May 31 2019.

  19. Efficacy and safety of BI 655066/ABBV-066 (risankizumab) in patients with severe persistent asthma—study results—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/results/NCT02443298?term=risankizumab&draw=3&rank=14. Accessed May 31 2019.

  20. A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa—full text view—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03926169?term=risankizumab&draw=2&rank=2. Accessed May 31 2019.

  21. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7. https://doi.org/10.1016/j.jaci.2015.01.018.

    Article  CAS  PubMed  Google Scholar 

  22. Suleiman AA, Khatri A, Minocha M, Othman AA. Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn’s disease: analyses of phase I and II trials. Clin Pharmacokinet. 2019;58(3):375–87. https://doi.org/10.1007/s40262-018-0704-z.

    Article  CAS  PubMed  Google Scholar 

  23. Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA. Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I–III clinical trials. Clin Pharmacokinet. 2019;58:1309–21. https://doi.org/10.1007/s40262-019-00759-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sun Pharma I. Skyrizi (risankizumab) [package insert]. https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

  25. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–72. https://doi.org/10.1016/j.jaad.2018.11.057.

    Article  PubMed  Google Scholar 

  26. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61. https://doi.org/10.1016/S0140-6736(18)31713-6.

    Article  CAS  PubMed  Google Scholar 

  27. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 psoriasis studies. AbbVie News Center. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantly-greater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm. Accessed June 1 2019.

  28. Blauvelt A, Papp KA, Gooderham M, et al. Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial; abstract presented at: psoriasis from gene to clinic; November 30 to December 2017.

    Google Scholar 

  29. Risankizumab meets all primary endpoints reporting positive results in fourth pivotal phase 3 psoriasis study. AbbVie News Center. https://news.abbvie.com/news/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasis-study.htm. Accessed June 1 2019.

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Nebraska Medical Center, Omaha, NE, USA

    Erica B. Lee

  2. Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA

    Deeti J. Pithadia

  3. Department of Internal Medicine, Kettering Hospital Network, Kettering, OH, USA

    Kelly A. Reynolds

  4. Dermatology Research and Education Foundation, Irvine, CA, USA

    Jashin J. Wu

Authors
  1. Erica B. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Deeti J. Pithadia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kelly A. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jashin J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, Suite 11D, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Jeffrey M. Weinberg

  2. Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Mark Lebwohl

Ethics declarations

Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis; a consultant for AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Dermira, Dr. Reddy’s Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Promius Pharma, Regeneron, Sun Pharmaceutical, and UCB, Valeant Pharmaceuticals North America LLC; and a speaker for AbbVie, Celgene, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, Valeant Pharmaceuticals North America LLC. The rest of the authors have no conflicts to disclose.

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lee, E.B., Pithadia, D.J., Reynolds, K.A., Wu, J.J. (2021). Risankizumab. In: Weinberg, J.M., Lebwohl, M. (eds) Advances in Psoriasis. Springer, Cham. https://doi.org/10.1007/978-3-030-54859-9_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-54859-9_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-54858-2

  • Online ISBN: 978-3-030-54859-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation